| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82d90a428fe59642f7844544f20f980d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2999-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10041
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0083
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0075 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0083
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 |
| filingDate |
2014-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_773845d5d0636500318d657bf0f39268
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3725c1f3a10359afbbf5aa1632818128 |
| publicationDate |
2015-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015038559-A1 |
| titleOfInvention |
Pharmaceutical Composition and Method for the Treatment of Neurodegenerative Diseases, in Particular Amyotrophic Lateral Sclerosis |
| abstract |
A pharmaceutical composition and method for therapy of neurodegenerative diseases including amyotrophic lateral sclerosis, the composition comprising an adenoviral vector, expressing a human angiogenesis factor gene; an effective amount of the adenoviral vector in the form of a non-replicating nanoparticle based on a genome of human adenovirus type 5 with an insertion of a human angiogenin gene which produces the human angiogenesis in a human body; a non-replicating nanoparticle based on the genome of human adenovirus type 5 with an insertion of a human vascular endothelium growth factor gene; and a formulating buffer; wherein the human angiogenin factor gene and the human vascular endothelium growth factor gene are cloned in two expression cassettes within one non-replicating nanoparticle based on the genome of human adenovirus type 5. |
| priorityDate |
2012-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |